LPTN Share Price

Open 2.52 Change Price %
High 2.67 1 Day 0.12 4.80
Low 2.52 1 Week 0.03 1.16
Close 2.62 1 Month -0.19 -6.76
Volume 25991 1 Year 2.37 948.00
52 Week High 4.09
52 Week Low 0.00
LPTN Important Levels
Resistance 2 2.76
Resistance 1 2.70
Pivot 2.60
Support 1 2.54
Support 2 2.48
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Lpath, Inc. (NASDAQ: LPTN)

LPTN Technical Analysis 1.5
As on 9th Dec 2016 LPTN Share Price closed @ 2.62 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.47 & Sell for SHORT-TERM with Stoploss of 2.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
LPTN Target for December
1st Target up-side 3
2nd Target up-side 3.37
3rd Target up-side 3.74
1st Target down-side 1.96
2nd Target down-side 1.59
3rd Target down-side 1.22
LPTN Other Details
Segment EQ
Market Capital 68592976.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.lpath.com
LPTN Address
LPTN
4025 Sorrento Valley Boulevard
San Diego, CA 92121
United States
Phone: 858-678-0800
Fax: 858-678-0900
LPTN Latest News
Shares in Review: Lpath, Inc. (NASDAQ:LPTN)   Wall Street Beacon   - 07th Dec 16
Update on Penny Stock: Investors Checking In On Lpath, Inc. (NASDAQ:LPTN)   Duncan Research   - 07th Dec 16
Stock Update (NASDAQ:LPTN): Lpath, Inc. and Apollo Endosurgery Sign Merger ...   Smarter Analyst   - 09th Sep 16
Latest Lpath Inc. (NASDAQ:LPTN) Target Price Suggests Stock Is Worth $11/Share   Review Fortune   - 23rd Aug 16
what are Analysts saying about: Lpath, Inc. (NASDAQ:LPTN)   News Oracle   - 22nd Aug 16
Lpath Reports Favorable Results from Phase 1 Study of Lpathomab   PR Newswire (press release)   - 19th Apr 16
Lpath Inc. shares plummet on test failures   MarketWatch   - 20th May 15
Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering   PR Newswire (press release)   - 29th Sep 14
News Lpath Inc.LPTN   Wall Street Journal   - 14th Jul 11
Plus the latest data from Realtor.com on 21 home markets across the US   MarketWatch   - 22nd Apr 11
Interactive Technical Analysis Chart Lpath, Inc. ( LPTN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Lpath, Inc.
LPTN Business Profile
Lpath, Inc. (Lpath) is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Company's program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma. Lpath's third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.